A Randomized Double-Blind Phase 3 Trial Comparing EC145 and Pegylated Liposomal Doxorubicin (PLD/Doxil/Caelyx) in Combination Versus PLD in Participants With Platinum-Resistant Ovarian Cancer

Trial Profile

A Randomized Double-Blind Phase 3 Trial Comparing EC145 and Pegylated Liposomal Doxorubicin (PLD/Doxil/Caelyx) in Combination Versus PLD in Participants With Platinum-Resistant Ovarian Cancer

Suspended
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Technetium Tc99m etarfolatide (Primary) ; Vintafolide (Primary) ; Doxorubicin liposomal
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Biomarker; Registrational; Therapeutic Use
  • Acronyms PROCEED
  • Sponsors Endocyte; Merck Sharp & Dohme
  • Most Recent Events

    • 08 Jun 2016 Last checked against United Kingdom Clinical Research Network.
    • 20 Mar 2015 Results will be presented at the 2015 Annual Meeting on Women's Cancer in Chicago in March 2015, according to an Endocyte media release.
    • 19 May 2014 Merck and Endocyte will take steps to terminate the PROCEED trial and will provide investigators with instructions to conclude the trial. The study results will be presented in a future scientific congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top